PMID- 23547079
OWN - NLM
STAT- MEDLINE
DCOM- 20130726
LR  - 20201219
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Linking)
VI  - 31
IP  - 16
DP  - 2013 Jun 1
TI  - 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage 
      follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 
      years from the International, Randomized, Phase III First-LineIndolent trial.
PG  - 1977-83
LID - 10.1200/JCO.2012.45.6400 [doi]
AB  - PURPOSE: Updated results are presented after a median follow-up of 7.3 years from 
      the phase III First-Line Indolent Trial of yttrium-90 ((90)Y) -ibritumomab 
      tiuxetan in advanced-stage follicular lymphoma (FL) in first remission. PATIENTS 
      AND METHODS: Patients with CD20(+) stage III or IV FL with complete response 
      (CR), unconfirmed CR (CRu), or partial response (PR) after first-line induction 
      treatment were randomly assigned to (90)Y-ibritumomab consolidation therapy 
      (rituximab 250 mg/m(2) days -7 and 0, then (90)Y-ibritumomab 14.8 MBq/kg day 0; 
      maximum 1,184 MBq) or no further treatment (control). Primary end point was 
      progression-free survival (PFS) from date of random assignment. RESULTS: For 409 
      patients available for analysis ((90)Y-ibritumomab, n = 207; control, n = 202), 
      estimated 8-year overall PFS was 41% with (90)Y-ibritumomab versus 22% for 
      control (hazard ratio [HR], 0.47; P < .001). For patients in CR/CRu after 
      induction, 8-year PFS with (90)Y-ibritumomab was 48% versus 32% for control (HR, 
      0.61; P = .008), and for PR patients, it was 33% versus 10% (HR, 0.38; P < .001). 
      For (90)Y-ibritumomab consolidation, median PFS was 4.1 years (v 1.1 years for 
      control; P < .001). Median time to next treatment (TTNT) was 8.1 years for 
      (90)Y-ibritumomab versus 3.0 years for control (P < .001) with approximately 80% 
      response rates to second-line therapy in either arm, including autologous 
      stem-cell transplantation. No unexpected toxicities emerged during long-term 
      follow-up. Estimated between-group 8-year overall survival rates were similar. 
      Annualized incidence rate of myelodysplastic syndrome/acute myeloblastic leukemia 
      was 0.50% versus 0.07% in (90)Y-ibritumomab and control groups, respectively (P = 
      .042). CONCLUSION: (90)Y-ibritumomab consolidation after achieving PR or CR/CRu 
      to induction confers 3-year benefit in median PFS with durable 19% PFS advantage 
      at 8 years and improves TTNT by 5.1 years for patients with advanced FL.
FAU - Morschhauser, Franck
AU  - Morschhauser F
AD  - Centre Hospitalier Universitaire, Lille, France. 
      franck.morschhauser@chru-lille.fr
FAU - Radford, John
AU  - Radford J
FAU - Van Hoof, Achiel
AU  - Van Hoof A
FAU - Botto, Barbara
AU  - Botto B
FAU - Rohatiner, Ama Z S
AU  - Rohatiner AZ
FAU - Salles, Gilles
AU  - Salles G
FAU - Soubeyran, Pierre
AU  - Soubeyran P
FAU - Tilly, Herve
AU  - Tilly H
FAU - Bischof-Delaloye, Angelika
AU  - Bischof-Delaloye A
FAU - van Putten, Wim L J
AU  - van Putten WL
FAU - Kylstra, Jelle W
AU  - Kylstra JW
FAU - Hagenbeek, Anton
AU  - Hagenbeek A
LA  - eng
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20130401
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Yttrium Radioisotopes)
RN  - 4Q52C550XK (ibritumomab tiuxetan)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Antineoplastic Agents/*therapeutic use
MH  - Disease-Free Survival
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - International Cooperation
MH  - Kaplan-Meier Estimate
MH  - Lymphoma, Follicular/drug therapy/pathology/radiotherapy/*therapy
MH  - Maintenance Chemotherapy
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Neoplasms, Second Primary/diagnosis/etiology
MH  - Radioimmunotherapy/*methods
MH  - Time Factors
MH  - Treatment Outcome
MH  - Yttrium Radioisotopes/therapeutic use
EDAT- 2013/04/03 06:00
MHDA- 2013/07/28 06:00
CRDT- 2013/04/03 06:00
PHST- 2013/04/03 06:00 [entrez]
PHST- 2013/04/03 06:00 [pubmed]
PHST- 2013/07/28 06:00 [medline]
AID - JCO.2012.45.6400 [pii]
AID - 10.1200/JCO.2012.45.6400 [doi]
PST - ppublish
SO  - J Clin Oncol. 2013 Jun 1;31(16):1977-83. doi: 10.1200/JCO.2012.45.6400. Epub 2013 
      Apr 1.